Article
A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.
Cancer biology & therapy - 3 Aug 2018
Liu Qiuli, Tong Dali, Liu Gaolei, Yi Yuting, Xu Jing, Yang Xingxia, Wang Linang, Zhang Jun, Ye Jin, Zhang Yao, Yuan Gang, Wang Peng, Chen Rongrong, Guan Yanfang, Yi Xin, Zhang Dianzheng, Jiang Jun
Abstract excerpt
Genetic factors contribute to more than 40% of prostate cancer risk, and mutations in BRCA1 and BRCA2 are well-established risk factors. By using target capture-based deep sequencing to identify potential pathogenic germline mutations, followed by Sanger sequencing to determine the loci of the mutations, we identified a novel pathogenic BRCA2 mutation caused by a cytosine-to-guanine base substitution at position...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.